HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sophia Adamia Selected Research

Therapeutics

6/2022Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
1/2022Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
11/2020The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
9/2013Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?
4/2011Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
9/2010Discovery and characterization of novel mutant FLT3 kinase inhibitors.
1/2009Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
9/2007Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
8/2007Novel agents in the treatment of Waldenström's macroglobulinemia.
7/2007Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sophia Adamia Research Topics

Disease

14Neoplasms (Cancer)
01/2020 - 04/2003
12Multiple Myeloma
06/2022 - 08/2004
6Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2020 - 09/2010
5Waldenstrom Macroglobulinemia (Macroglobulinemia)
01/2009 - 03/2005
4Leukemia
12/2020 - 05/2008
3BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/2013 - 05/2008
2Breast Neoplasms (Breast Cancer)
01/2014 - 03/2011
2Carcinogenesis
05/2013 - 02/2005
2Disease Progression
12/2008 - 06/2005
1Systemic Mastocytosis
11/2019
1Genomic Instability
03/2016
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
09/2015
1Hypereosinophilic Syndrome (Loeffler Endocarditis)
05/2010
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
05/2010
1Lymphoma (Lymphomas)
01/2009
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2009
1Paraproteinemias (Monoclonal Gammopathy)
08/2007
1Residual Neoplasm
07/2007

Drug/Important Bio-Agent (IBA)

8Hyaluronan SynthasesIBA
01/2014 - 04/2003
5Hyaluronic Acid (Hyaluronan)IBA
01/2014 - 04/2003
4Proteins (Proteins, Gene)FDA Link
12/2020 - 04/2003
3Phosphotransferases (Kinase)IBA
11/2019 - 01/2011
3Pharmaceutical PreparationsIBA
09/2013 - 05/2008
2Monoclonal AntibodiesIBA
11/2020 - 08/2007
2MicroRNAs (MicroRNA)IBA
01/2020 - 10/2010
2RNA Precursors (Precursor, mRNA)IBA
01/2014 - 05/2013
2Imatinib Mesylate (Gleevec)FDA Link
09/2013 - 05/2008
2Indicators and Reagents (Reagents)IBA
05/2013 - 06/2005
2Immunoglobulin M (IgM)IBA
09/2007 - 08/2007
1venetoclaxIBA
12/2020
1S63845IBA
12/2020
1daratumumabIBA
11/2020
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2020
1Ligases (Synthetase)IBA
01/2020
1UbiquitinIBA
01/2020
1gilteritinibIBA
11/2019
1avapritinibIBA
11/2019
1midostaurinIBA
11/2019
1tyrosine receptor (receptor, tyrosine)IBA
11/2019
1quizartinibIBA
11/2019
1crenolanibIBA
11/2019
1Sorafenib (BAY 43-9006)FDA Link
11/2019
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2019
1alpha-hydroxyglutarateIBA
01/2019
1Histone Deacetylases (Histone Deacetylase)IBA
03/2016
1NAD (NADH)IBA
03/2016
1N- (4- (1- benzoylpiperidin- 4- yl)butyl)- 3- (pyridin- 3- yl)acrylamideIBA
09/2015
1Cyclosporine (Ciclosporin)FDA LinkGeneric
09/2015
1Nicotinamide PhosphoribosyltransferaseIBA
09/2015
1Lenalidomide (CC 5013)FDA Link
04/2011
1Biomarkers (Surrogate Marker)IBA
03/2011
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2010
1Platelet-Derived Growth Factor alpha ReceptorIBA
05/2010
1Adenosine Triphosphate (ATP)IBA
05/2010
1nasIBA
01/2009
1NucleosidesIBA
01/2009
1nilotinibFDA Link
05/2008
1Tyrosine Kinase InhibitorsIBA
05/2008
1Immunologic Factors (Immunomodulators)IBA
08/2007
1LigandsIBA
08/2007
1CholesterolIBA
08/2007
1Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
08/2007
1Biological ProductsIBA
08/2007
1Thalidomide (Thalomid)FDA Link
08/2007
1Bortezomib (Velcade)FDA Link
08/2007
1Rituximab (Mabthera)FDA Link
08/2007
1Stem Cell FactorIBA
08/2007
1Protein Kinase C betaIBA
08/2007
1B-Cell Activating FactorIBA
08/2007
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
08/2007
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
07/2007
1DNA (Deoxyribonucleic Acid)IBA
10/2005
1Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
10/2005
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2005
1Protein Isoforms (Isoforms)IBA
08/2004

Therapy/Procedure

10Therapeutics
06/2022 - 07/2007
1Drug Therapy (Chemotherapy)
01/2019
1Stem Cell Transplantation
08/2007
1Ambulatory Care (Outpatient Care)
10/2005
1Microelectrodes
09/2004